Trellis raises $9M to expose implant infections to antibiotics

Trellis Bioscience has closed a $9 million Series C backed by existing investors New Science Ventures and Easton Capital, alongside the AMR Action Fund and specialist medical investors.

What happened

The funding will support a Phase 2 study of calpurbatug, also known as TRL1068, for chronic infections involving prosthetic joints. The antibody is designed to disrupt bacterial biofilms so that conventional antibiotics and the immune system can reach the bacteria more effectively. The trial is fully enrolled, with headline results expected in 2027.

Why it matters

Biofilms form protective structures around bacteria, making implant-related infections difficult to eliminate. Patients may require prolonged antibiotics, repeated procedures or removal of the implant. A treatment that breaks down the biofilm could improve the effectiveness of existing drugs without relying on an entirely new antibiotic.

The bigger picture

Antimicrobial resistance and chronic implant infections remain major clinical challenges. Trellis has a plausible biological mechanism and regulatory support, but clinical effectiveness has not yet been demonstrated. The next trial will be crucial in determining whether the approach can produce meaningful patient outcomes and reduce the need for major surgery.